



# Corrigendum to “Bispecific antibodies” [Drug Discov. Today 20 (July (7)) (2015) 838–847]

Roland E. Kontermann<sup>1</sup> and Ulrich Brinkmann<sup>2</sup>, [ulrich.brinkmann@roche.com](mailto:ulrich.brinkmann@roche.com)



<sup>1</sup>Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany

<sup>2</sup>Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Penzberg, Penzberg, Germany

The authors regret errors in our review “Bispecific antibodies” in 2015 that have been brought to our attention. The bsAb LY3164530 was incorrectly placed into the “H-chain heterodimer/orthogonal Fab interface” class. Instead, LY3164530 was published in 2016 to be an engineered mAb-scFv fusion protein (<MET> IgG4 with HC N-terminal <EGFR> scFv fusions, Ling Liu et al. AACR Proceedings; Cancer Res 2016;76, 14 Suppl.: Abstract 873). We wish to also correct that SAR156597 is a bsAb developed by Sanofi (not Serono). The authors would like to apologise for any inconvenience caused and thank our colleagues which made us aware of it.

DOI of original article: [10.1016/j.drudis.2015.02.008](https://doi.org/10.1016/j.drudis.2015.02.008)  
Corresponding author: Brinkmann, U. ([ulrich.brinkmann@roche.com](mailto:ulrich.brinkmann@roche.com))